

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58447 A1

(51) International Patent Classification⁷: **A61K 31/44**,
9/48, 9/52, 9/54, 9/22, 9/26, 9/14, 9/50, A61F 13/00, 9/02

(21) International Application Number: PCT/US01/04347

(22) International Filing Date: 8 February 2001 (08.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/181,369 8 February 2000 (08.02.2000) US

(71) Applicant (for all designated States except US): **EURO-
CELTIQUE, S.A.** [LU/LU]; 122, Boulevard de la Petrusse,
L-2330 Luxembourg (LU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **OSHLACK, Ben-
jamin** [AU/US]; 351 East 84th Street, New York, NY
10028 (US). **CURTIS, Wright** [US/US]; 1 Jarvis Street,
Norwalk, CT 06851 (US).

(74) Agents: **DAVIDSON, Clifford, M.** et al.; Davidson
Davidson & Kappel, LLC, 14th Floor, 485 Seventh Av-
enue, New York, NY 10018 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CONTROLLED-RELEASE COMPOSITIONS CONTAINING OPIOID AGONIST AND ANTAGONIST

(57) Abstract: Controlled-release dosage forms containing an opioid agonist; and opioid antagonist; and a controlled release mate-
rial release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of said opioid
antagonist effective to attenuate a side effect of said opioid agonist. The dosage form provides analgesia for at least about 8 hours
when administered to human patients. In other embodiments, the dose of antagonist released during the dosing interval enhances the
analgesic potency of the opioid agonist.



WO 01/58447 A1